Transdermal Drug Delivery Articles
-
Nuances Of The Growing U.S. Market For Advanced Wound Dressings
9/13/2024
The U.S. market is continuing its shift away from traditional wound dressings (gauze, tape, etc.) toward advanced wound care (moist dressings, antimicrobial dressings, etc.).
-
Preparing For The FDA QMSR: Will You Be Ready?
9/3/2024
The new FDA Quality Management System Regulation (QMSR) becomes effective in February 2026. In this article, Fran DeGrazio discusses the implications for combination product and medical device developers as they prepare to demonstrate QMSR compliance.
-
FDA Issues Draft Guidance On Use-Related Risk Analysis (URRA)
8/14/2024
The FDA released a new draft guidance, "Purpose and Content of Use-Related Risk Analyses for Drugs, Biological Products, and Combination Products," in July. The public comment period closes on Sept. 9, 2024.
-
Setting The Bar For Drug Product Quality, Part 2: The Evolving Practice Of Particle Testing
7/29/2024
In Part 2 of a two-part series, Fran DeGrazio explains why best practices in particle testing and related risk-based approaches to product quality should not wait for official regulatory guidances and standards to catch up.
-
Setting The Bar For Drug Product Quality, Part 1: How Best Practices Prevail
7/29/2024
Regulatory guidance and standards, in official documentation, tend to emerge at a slower pace than do industry best practices. In Part1 of a two-part series, Fran DeGrazio explains why biopharma companies should build and apply best practices in advance of official regulations regarding drug product quality.
-
Embrace Packaging and Delivery Systems Designed for Today's Standards
7/1/2024
Regulations and standards for drug delivery systems and packaging are ever evolving and expanding, making it harder and more costly for older products to meet them. In this article, Fran DeGrazio explains why it is imperative that pharma companies consider new product adoption.
-
The Key to Regulatory Innovation? Global Harmonization
6/4/2024
Innovation in drug development and delivery is often thought of as purely a technical matter. In this article, Fran DeGrazio illustrates why innovation must also be applied to regulatory practices.
-
Balancing Sustainability With Patient Safety In Medical Device Design
6/3/2024
There is increasing pressure on manufacturers to make devices that combine safety and effectiveness with sustainability, particularly with regard to EU regulations and directives.
-
Quick Read: FDA's New Draft Guidance On Data Integrity For In Vivo BA/BE Studies
5/24/2024
The FDA has released a draft guidance, Data Integrity for In Vivo Bioavailability and Bioequivalence Studies. This article shares a concise summary. The FDA is accepting public comments through June 3.
-
A Critical Analysis Of FDA Human Factors IFU Guidance For Drug Delivery Devices
5/8/2024
Drug administration by lay users is becoming more common. Is current FDA guidance viable for demonstrating safe and effective use for critical devices and systems? No.